X

Trial Profile

Phase 2 Study To Determine the Safety and Efficacy of TTHX1114(NM141) on the Regeneration and Migration of Corneal Endothelial Cells in Patients Undergoing DWEK/DSO

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TTHX 1114 (Primary)
Indications Fuchs' endothelial dystrophy
Focus Therapeutic Use
Acronyms STORM
Sponsors Trefoil Therapeutics

Most Recent Events

06 Nov 2023 Status changed from active, no longer recruiting to completed.
08 May 2023 According to a Trefoil Therapeutics media release, results rom this trial presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
08 May 2023 Results published in the Trefoil Therapeutics Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com